Verona Pharma PLC
VRNA
ISIN null / Valor 36485349
Verona Pharma PLC
UMushroom community rating:
About company
Verona Pharma PLC is a pharmaceutical company specializing in the development of respiratory therapies, with a primary focus on treating chronic obstructive pulmonary disease (COPD). The company is advancing a fixed-dose combination formulation of ensifentrine, a novel dual inhibitor, with glycopyrrolate, a long-acting muscarinic antagonist, for maintenance treatment via nebulizers. Verona Pharma is also exploring other delivery methods, such as dry powder inhalers (DPI) and pressurized metered dose inhalers (pMDI), to expand its product lifecycle and collaboration opportunities. While initially targeting the U.S. market, the company has entered a $219 million strategic partnership with Nuance Pharma to develop and commercialize ensifentrine in Greater China, where COPD affects an estimated 100 million people. Beyond COPD, Verona Pharma's pipeline addresses other respiratory conditions with unmet medical needs, including non-cystic fibrosis bronchiectasis (NCFBE), cystic fibrosis, and asthma.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
9215 M
Market cap (USD)
Daily traded volume (Shares)
47.28 / 45.35
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
